Skip to main content

Table 1 Summary of studies included in the meta-analysis

From: The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials

Study

No. of patients

Inclusion period

Group

Histology (WHO grade, No.)

Stage

Radiotherapy

Chemotherapy

    

I

II

III

  

Concurrent

Adjuvant

Kwong et al, [10] 2004

165

1995-2001

CCRT RT

1 1

14 4

95

50

AJCC stage II -IV, any T, any N

2.5GyFx/5days/wk, primary site- 68Gy, Nodes- 66Gy, + 10Gy boost dose were given for pharyngeal extension and residual nodes

UFT 200 mg/day/7 days a wk

Alternating Cisplatin 100 mg/m2 day1 and 5FU 1 gm/m2/d day 1-3 and VBM regimen (Vincristine 2 mg, bleomycin 30 mg, MTX 150 mg/m2) every 3wks for 6 cycles.

Chan et al, [11] 2005

350

1994-1997

CCRT RT

2 1

12 7

160 168

AJCC stage II to IV, any T, any N, M0

66Gy in 33Fx per 6.5 wks + additional boost in case of parapharyngeal extension, residual neck nodes, and/or residual nasopharyngeal disease (Brachytherapy)

Cisplatin 40 mg/m2 in day1 weekly

None

Wee et al, [12] 2005

221

1997-2003

CCRT RT

-

100% grade II and III

AJCC stage II to IV, any T, any N

70Gy (2Gy/d in 5Fx/wk for 7 wks)

CDDP 25 mg/m2/d for 4 days, alternatively 30/30/40 mg/m2/d for 3 days if patient starts RT on Wednesday

CDDP 20 mg/m2/d × 4 days, 5FU 1000 mg/m2/d × 4 days

Lee et al, [13, 18] 2005,2010

348

1999-2004

CCRT RT

-

100% grade II

AJCC stage III and IV, any T, N2 or N3, M0

≥66Gy (2Gy/Fx/d, 5Fx/wk) + additional boosts to the parapharyngeal space, the primary or nodal sites when indicated not exceeding 20Gy

Cisplatin 100 mg/m2 × 3wks on days 1,22,43

CDDP 80 mg/m2 and 5FU 1000 mg/m2/d every 4 wks on days 71,99 and 127

Zhang et al, [14] 2005

115

2001-2003

CCRT RT

-

100% grade II and III

AJCC stage III and IV, any T, N2 or N3, M0

70-74Gy (2Gy/Fx/d, 5fx/wk) + additional boost in case of parapharyngeal extension, residual neck nodes and/or residual nasopharyngeal disease

6× Oxaliplatin 70 mg/m2 weekly

None

Lee et al, [15, 17] 2006,2009

93

1999-2004

CCRT RT

-

100% grade II

AJCC stage III and IV, T3-4, N0-1, M0

≥66Gy (2Gy/Fx/d, 5Fx/wk) + Additional boosts to the parapharyngeal space, the primary or nodal sites when indicated not exceeding 20Gy

Cisplatin 100 mg/m2 × 3wks on days 1,22,43

Cisplatin 80 mg/m2 and 5FU 1000 mg/m2/d on days 71,99 and 127

Chen et al, [16] 2008

316

2002-2005

CCRT RT

-

100% grade II and III

AJCC stage III and IVA-B, T1-4, N0-3,

≥68Gy (2Gy/Fx/d, 5Fx/wk) in 7 weeks + additional boost in case of parapharyngeal extension, residual neck nodes and/or residual nasopharyngeal disease

Cisplatin 40 mg/m2 day1 weekly × 7wks

Cisplatin 80 mg/m2 day1 and 5FU 800 mg/m2/d on days1-5 every 4wks for 3 cycles.

  1. Abbreviation: CDDP, Cisplatin; UICC, International Union Against Cancer; AJCC, American Joint Committee on cancer; FU, Fluorouracil
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us